Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228265 | 0.69 | ALB (0.36) | ALB | |
| SCHEMBL19242529 | 0.68 | ALB (0.35) | ALB | |
| SCHEMBL10137844 | 0.68 | ADORA2A (0.38) | ALB | |
| SCHEMBL12894749 | 0.66 | ALB (0.36) | ALB | |
| SCHEMBL12894752 | 0.65 | EP300 (0.33) | ALB | |
| SCHEMBL22139347 | 0.65 | ALB (0.36) | ALB | |
| SCHEMBL18744107 | 0.65 | EP300 (0.32) | ALB | |
| SCHEMBL12741722 | 0.64 | EP300 (0.41) | ALB | |
| SCHEMBL22139331 | 0.63 | ALB (0.35) | ALB | |
| SCHEMBL12741728 | 0.63 | EP300 (0.41) | ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171039-A1 | COMBINATIONS AND USES AND TREATMENTS | VIIV HEALTHCARE COMPANY | 2020-06-04 | — | — | US | disclosed |
| WO-2019030626-A1 | COMBINATIONS AND USES AND TREATMENTS THEREOF | VIIV HEALTHCARE COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171039-A1 | COMBINATIONS AND USES AND TREATMENTS | TYMP, DCTD, TPMT | ALB 2941/4885POLG 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.